I
21.74
-0.33 (-1.50%)
| Previous Close | 22.07 |
| Open | 22.14 |
| Volume | 1,469,318 |
| Avg. Volume (3M) | 1,022,536 |
| Market Cap | 3,692,147,712 |
| Price / Book | 8.35 |
| 52 Weeks Range | |
| Earnings Date | 3 Feb 2025 - 4 Feb 2025 |
| Diluted EPS (TTM) | -2.21 |
| Total Debt/Equity (MRQ) | 0.01% |
| Current Ratio (MRQ) | 7.61 |
| Operating Cash Flow (TTM) | -271.64 M |
| Levered Free Cash Flow (TTM) | -160.83 M |
| Return on Assets (TTM) | -54.54% |
| Return on Equity (TTM) | -92.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Immunovant, Inc. | Bearish | Bearish |
AIStockmoo Score
0.8
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | 5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.80 |
|
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 58.10% |
| % Held by Institutions | 47.18% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 51.00 (HC Wainwright & Co., 134.59%) | Buy |
| Median | 45.00 (106.99%) | |
| Low | 45.00 (B of A Securities, 106.99%) | Buy |
| 45.00 (Wells Fargo, 106.99%) | Buy | |
| Average | 47.00 (116.19%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 26.90 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 15 Jan 2025 | 45.00 (106.99%) | Buy | 24.40 |
| Wells Fargo | 19 Dec 2024 | 45.00 (106.99%) | Buy | 25.66 |
| HC Wainwright & Co. | 08 Nov 2024 | 51.00 (134.59%) | Buy | 30.65 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GEFFNER MICHAEL | - | 23.23 | -2,657 | -61,722 |
| STOUT JAY S | - | 23.23 | -2,195 | -50,990 |
| Aggregate Net Quantity | -4,852 | |||
| Aggregate Net Value ($) | -112,712 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 23.23 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GEFFNER MICHAEL | Officer | 22 Jan 2025 | Sell (-) | 2,657 | 23.23 | 61,722 |
| STOUT JAY S | Officer | 22 Jan 2025 | Sell (-) | 2,195 | 23.23 | 50,990 |
| Date | Type | Details |
|---|---|---|
| 13 Jan 2025 | Announcement | Immunovant Announces $450 Million Private Placement |
| 07 Nov 2024 | Announcement | Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |